Preclinical Humanized CTLA-4 Mouse Model
Design of the hCTLA-4 mouse
The humanized CTLA‑4 mouse model (hCTLA-4) is developed by Knockin at the mouse CTLA‑4 locus, and enables the expression of: a) the full-length chimeric CTLA-4 isoform; and b) the soluble isoform.
The design also gives access to CTLA-4 conditional Knockout mice for a tissue-specific assessment of compounds’ specificity and toxicity.
Applications in immuno-oncology
The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.
Access to conditional CTLA-4 Knockout mouse:
The conditional Knockout model allows the tissue-specific assessment of compounds’ specificity and toxicity.
See also:
- Double-humanized hPD-1/hCTLA-4 mouse model
- Double-humanized hCTLA-4/hLAG3 mouse model
|
Request a quote here to get pricing, offers and hCTLA-4 model information by phone or email. |
hCTLA-4 features
- The CTLA-4 extracellular domain is entirely humanized
- Physiological regulation and expression pattern of the human CTLA-4
- Preservation of the target-ligand interaction
- Fully functional mouse immune system
- Lack of expression of the murine target gene, thus avoiding cross-reactivity
hCTLA-4 validation*
The model has been co-validated by Charles River, our partner of the precompetitive consortium of company leaders in immuno-oncology and immunotherapy.
A scientific poster was presented at the Tumour Models 2019 in London. Download poster
|
hCTLA-4 expression pattern recapitulates mCTLA-4 hCTLA-4 and mCTLA-4 expression on αCD3-activated splenocytes on A) Tregs (viable, CD3+CD4+CD25+Foxp3+), B) conventional CD4+ (viable, CD3+CD4+Foxp3-) at day 3, and C) CD8+ (viable, CD3+CD8+) T cells at indicated time points. |
|
In vivo anti-tumor activity is observed in response to ipilimumab in hCTLA‑4 mice
Wild-type and hCTLA-4 mice were implanted s.c. with MC38 tumor on day 0 with n=10 mice per group. Survival of mice treated with αhCTLA-4 (ipilimumab), αmCTLA-4 (9H10) or isotype i.p. bi-weekly for 2 weeks. |
* For more validation data please contact us.
Further reading
- Uncoupling Efficacy from Toxicity: A Case Study on MEDI5752
- Uncoupling Toxicity from Therapeutic Efficacy: A Case Study on ATOR-1015
- Uncoupling Toxicity from Therapeutic Efficacy: The New Challenge of Immunotherapies
- Humanized Immune Checkpoint Mouse Models for Immuno-Oncology Studies
- A new Nature report by BMS provides new insights into VISTA biology and design of combination therapies
- Immune checkpoint inhibitors: A strategy to tackle cancer?
Ready to be shipped to your lab
- Cohorts available upon request
- Studies can be carried out at your site or at your favorite CRO
- SOPF certification and worldwide delivery by professional breeders
- Models provided with FTO on patent-protected technologies used for model generation
|
Are you looking for another target? Follow this link humanized immune checkpoint (ICP) mouse models, or contact us. |